HIGHLIGHTS KUS121 was developed to selectively inhibit the adenosine triphosphatase activity of valosin-containing protein without affecting other cellular functions of valosin-containing protein.
SUMMARY
No effective treatment is yet available to reduce infarct size and improve clinical outcomes after acute myocardial infarction by enhancing early reperfusion therapy using primary percutaneous coronary intervention. The study showed that Kyoto University Substance 121 (KUS121) reduced endoplasmic reticulum stress, maintained adenosine triphosphate levels, and ameliorated the infarct size in a murine cardiac ischemia and reperfusion injury model. The study confirmed the cardioprotective effect of KUS121 in a porcine ischemia and reperfusion injury model. These findings confirmed that KUS121 is a promising novel therapeutic agent for myocardial infarction in conjunction with primary percutaneous coronary intervention. (1) . In the United States, more than 360,000 people died of IHD in 2015, and IHD accounted for 43.8% of deaths from cardiovascular disease (2) . In Japan, IHD accounted for 35.6% of deaths from heart disease in 2016 (3) .
In patients with acute myocardial infarction (MI), early reperfusion therapy using primary percutaneous coronary intervention (PCI) is performed to reduce the infarct size and improve outcomes (4) . However, when a larger infarct size remains after primary PCI, the rates of all-cause mortality and hospitalization for heart failure (HF) are still high (5) .
High mortality from HF and rehospitalization for HF are becoming serious concerns from both health care and medical cost perspectives (2, 6) .
To further reduce infarct sizes and improve clinical outcomes, new treatments in addition to early reperfusion therapy are needed. Indeed, drugs such as an inhibitor of Na þ /H þ exchanger and cyclosporine A were reported to have cardioprotective effects in animal experiments (7) or in small clinical trials (8) . However, these effects were not confirmed in multicenter, randomized, double-blind clinical trials (9, 10) . Although many other clinical trials of novel therapies for acute MI are ongoing, there are currently no therapeutic agents available to reduce infarct size and improve clinical outcomes (11) .
Valosin-containing protein (VCP) is a member of the adenosine triphosphatase (ATPase) associated with diverse cellular activities family, and it is expressed ubiquitously in almost all cell types. As reported previously, in addition to ATPase activity, VCP is involved in various cellular functions, including proteasome-mediated protein degradation, endoplasmic reticulum (ER)-associated degradation, lysosomal protein degradation, autophagy, cell cycle progression, membrane fusion, and so on (12) . Gainof-function mutations in VCP have been reported to cause inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) (13) , and IBMPFD-causing mutations in VCP result in elevated ATPase activity (14) . Indeed, KUS121 has been shown to maintain cellular adenosine triphosphate (ATP) levels, reduce ER stress, and prevent cell death in vitro without showing any toxic effects (16) . KUS121 has also been shown to elicit neuroprotective effects in murine retinitis pigmentosa models, murine glaucoma models, rat retinal ischemic injury models, and murine Parkinson's disease models (16) (17) (18) (19) .
Considering the cardiac phenotype in IBMPFD patients and the neuroprotective effect of KUS121 in vivo, we anticipated that KUS121 may produce a cardioprotective effect in IHD. In this study, we found that KUS121 preserved ATP levels, reduced ER stress, and suppressed cell death in H9C2 rat cardiomyoblast cells. Furthermore, in murine and porcine ischemia and reperfusion (I/R) injury models, KUS121 ameliorated cardiac damage and preserved cardiac function.
These results indicated that KUS121 is a promising novel therapeutic agent for MI. VCP expression was also confirmed in the mouse heart and its expression in cardiomyocytes was 2-fold higher than in fibroblasts ( Figure 1C ). It is known that ER stress and ischemia affect mitochondrial functions (22) (23) (24) ; therefore, we examined mitochondrial functions using an XF96 extracellular flux analyzer (Agilent Technologies, Santa Clara, California). H9C2 cells were treated with tunicamycin in the absence or presence of KUS121 for 6 h, and the oxygen consumption rate was measured ( Figure 3A) . The numbers of H9C2 cells in these conditions were similar to that in normal culture (Supplemental Figures 4B and 4C) . The expression of CHOP was significantly reduced in the border zone ( Figure 4D ).
METHODS
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In addition, to investigate the protective effects of were pseudo-colored using warmer colors and low FRET ratios (i.e., lower ATP levels) using cooler colors (Supplemental Figure 5A ). ATP levels in infarcted areas of KUS121-treated mice were significantly higher from 0 to 60 min after reperfusion (Supplemental Figures 5A and 5B ) than were those of control I/R mice, when KUS121 was administered before ischemia, as shown in Supplemental Figure 3A .
In noninfarcted areas of the LV, ATP levels in KUS121-treated mice were also higher than those of control I/R mice (Supplemental Figure 5C ). Although ATP levels in the right ventricle of KUS121-treated mice were similar to those of control mice (Supplemental Figure 5D ), the relative ATP ratio in the infarcted area to that in the right ventricle was higher in KUS121-treated mice than in control mice (Supplemental Figure 5E ).
Next, we examined whether KUS121 administration after reperfusion could also preserve ATP levels. As shown in Figure 4A , we administered the same amount of KUS121 immediately after reperfusion in I/R injury models of GO-ATeam2 mice. ATP levels in infarcted areas of KUS121-treated mice were the same as those of control mice during ischemia. However, ATP levels of KUS121-treated mice recovered immediately and significantly after KUS121 administration compared with control mice (Figures 6A and   6B ). These data indicate that KUS121 was able to preserve ATP levels in I/R models in vivo.
BENEFICIAL EFFECTS ARE OBSERVED WITH A SINGLE
ADMINISTRATION OF KUS121 AFTER REPERFUSION. We further examined whether a single KUS121 administration after reperfusion could benefit the infarcted area or not. As shown in Figure 7A , 25 mg/kg of KUS121 was injected intravenously, and the same amount was injected intraperitoneally immediately after reperfusion. The infarcted area-to-LV area ratio was significantly reduced in KUS121-treated mice at 7 days after reperfusion compared with control mice ( Figures 7B and 7C) . However, a dose of 16 mg/kg Cardioprotective Effect of KUS121 KUS121 (Supplemental Figure 6A) , failed to produce a beneficial effect (Supplemental Figures 6B and 6C ). Figure 8A) . Using double-staining with TTC and Evans blue, the infarcted area-to-AAR ratios of KUS121-treated pigs were found to be significantly lower than were those of the control pigs in a dose-dependent manner, although the AAR-to-LV ratios of KUS121-treated pigs were the same as those of control pigs (Figures 8B to   8D ). In addition, we confirmed that the appearance of infarcted areas, as determined using Masson's trichrome staining, was almost the same as that evaluated using TTC staining (Supplemental Figures 7A and 7B) . We also evaluated the infarcted area by late gadolinium enhancement with CMR ( Figure 8E) . The infarcted area-to-LV area ratios in KUS121-treated pigs were also significantly lower than were those of control pigs ( Figure 8F) . These data demonstrate that KUS121 intracoronary administration provides significant benefits in the presence of cardiac damage in porcine I/R injury models.
DISCUSSION
In this study, we investigated the cardioprotective effects of KUS121 using murine I/R injury models that mimic reperfusion therapy for MI, and we showed that KUS121 administration even after reperfusion was able to maintain ATP levels and attenuate the infarcted area. Echocardiographic evaluation KUS121 was developed to selectively inhibit the ATPase activity of VCP without affecting its other cellular functions, and previous studies demonstrated that KUS121 can maintain cellular ATP levels, reduce ER stress, and prevent cell death in vitro when challenged with many cell-death-inducing insults in many cell types (16) (17) (18) (19) . Consistent with the ability of KUS121 to maintain ATP levels and reduce ER stress, KUS121 has been reported to have neuroprotective effects in vivo (e.g., in models of murine retinitis pigmentosa, murine glaucoma, rat retinal ischemic injury, and murine Parkinson's disease) (16) (17) (18) (19) . In this study, we further demonstrated the close link among ER stress, decreased ATP levels, and cell death in the heart.
To the best of our knowledge, the cardioprotective mechanisms of KUS121 are quite different from other drugs that have been tested for the treatment of MI (7,28-30), making KUS121 virtually unique in its ability to maintain ATP levels in animal I/R injury models. Recently, LV mechanical support using Impella (Abiomed, Danvers, Massachusetts) was reported to reduce infarct size after I/R injury (31) . This was possibly due to a reduction in excessive myocardial energy demand relative to supply, which would be similar in principle to KUS121 administration in our in vivo models.
It is especially noteworthy that KUS121 is able to reduce infarct size by administration even after reperfusion, especially through intracoronary injection. This can be easily performed after primary PCI in everyday clinical practice. Thus, we concluded that KUS121 is a promising compound that could be used in conjunction with primary PCI for the treatment of MI.
STUDY LIMITATIONS. We showed that KUS121 reduced the infarct size in murine and porcine I/R injury models by maintaining ATP levels and reducing ER stress, but the detailed mechanism of the link among ER stress, decreased ATP levels, and cell death remains to be elucidated. Further investigations are needed to fully explore the complex signaling mechanisms that are at play during MI and reperfusion.
In porcine models, we evaluated the infarct size only at 7 days after reperfusion, but we did not evaluate the effect of KUS121 at later time points.
Moreover, we did not confirm the detailed safety of KUS121, although no obvious toxicity of KUS121 was observed in our study. We need to perform further studies with long-term follow-up to confirm the cardiac protective efficacy and safety of KUS121.
As previously reported (16, 32) , KUS121 was confirmed to inhibit the ATPase activity of recombinant VCP in vitro with half-maximal inhibitory concentration value of 330 nM, which is much lower than that of a VCP inhibitor, DBeQ (1 mM). However, we did not evaluate the specificity and off-target effects of KUS 121 in vivo. Further studies are need to elucidate them in vivo by analysis of the pharmacokinetics and pharmacodynamics of KUS121.
CONCLUSIONS
Here, we have shown that in I/R injury models, KUS121 reduced infarct size and preserved cardiac function by maintaining ATP levels and reducing ER stress. We also showed that this effect can be achieved by the administration of KUS121 only once after reperfusion, which was confirmed in porcine I/R models. Our study indicates that KUS121 is a promising therapeutic agent for MI in conjunction with primary PCI. Progression of studies leading to a Ide et al. TRANSLATIONAL OUTLOOK: We expect that KUS121 will one day be used in clinical practice. However, further studies are needed to investigate the pharmacokinetics and pharmacodynamics of KUS121, especially those after intracoronary KUS121 administration. Additionally, we need to verify the detailed safety of KUS121. If these are confirmed, the cardioprotective effects of KUS121 may be evaluated in clinical trials. Cardioprotective Effect of KUS121
